Meeting
2023 ASCO Annual Meeting
Phase 1 dose-expansion study of oral TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with Ewing sarcoma (EWS).
Authors
Gregory Michael Cote
MGH Cancer Center, Boston, MA
Gregory Michael Cote , Andrew J. Wagner , John A. Charlson , James S Hu , Mark Andrew Dickson , Gina Z. D'Amato , Sujan Kabir , Bo Xu , Claudia Lebedinsky , Margaret von Mehren
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03604783
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS11589)
DOI
10.1200/JCO.2023.41.16_suppl.TPS11589
Abstract #
TPS11589
Poster Bd #
518a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase 1 expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas.
First Author: Damon R. Reed
Poster
2020 ASCO Virtual Scientific Program
A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑1287 administered daily to patients with advanced solid tumors.
First Author: Ben George
Poster
2024 ASCO Breakthrough
SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.
First Author: Makoto Nishio
Poster
2024 ASCO Breakthrough
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.
First Author: Joohyuk Sohn